J&J back in court over new gener­ic threat from In­tas, just months af­ter fend­ing off Te­va

Three months af­ter suc­cess­ful­ly fend­ing off Te­va’s pro­posed gener­ic to its schiz­o­phre­nia drug In­ve­ga Susten­na, John­son & John­son’s Janssen unit is back in court ar­gu­ing an­oth­er case of al­leged patent in­fringe­ment — this time from In­tas Phar­ma­ceu­ti­cals and its sub­sidiary Ac­cord Health­care.

Janssen filed a com­plaint in the US Dis­trict Court of New Jer­sey on Wednes­day, claim­ing that Ac­cord’s ab­bre­vi­at­ed new drug ap­pli­ca­tion (AN­DA) for its gener­ic to In­ve­ga Susten­na in­fringes up­on the phar­ma gi­ant’s sole re­main­ing patent on the drug.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER